GMP Companies Licenses Breakthrough Anti-Infective Technology From Procter & Gamble

06-Feb-2004

The Procter & Gamble Company and GMP Companies, Inc. announced that P&G has licensed to GMP Companies, its newly-developed, novel topical anti-infective technology for exclusive worldwide use in medical settings and applications in addressing public health needs.

GMP Anti-Infective Solutions, Inc., a subsidiary of GMP Companies, will develop the technology for use as an antimicrobial hand rub solution and surgical scrub and preparation product. GMP Companies plans to broadly commercialize the technology for use in healthcare settings including hospitals, physician offices, outpatient medical facilities, home health care and veterinary medical facilities.

This non-alcohol-based technology uses a novel combination of active ingredients that is not currently available in the healthcare marketplace. In preliminary testing, it has demonstrated the ability to immediately kill deadly viruses, bacteria and other infectious agents. Further benefits may include residual activity and mildness on the skin.

"We are delighted to be working again in a strategic relationship with Procter & Gamble, a global leader in the development, manufacturing and marketing of a wide range of consumer products," said Rudyard Istvan, Executive Vice President of Global Strategy for GMP Companies. "We have licensed an important technology and look forward to bringing it to the healthcare marketplace."

The Centers for Disease Control and Prevention (CDC) estimates that each year nearly two million patients in the U.S. contract an infection while hospitalized. According to the CDC, approximately 90,000 hospital patients die each year as a result of these hospital acquired infections, and the cost of these infections to the U.S. healthcare system is estimated at $5 billion annually. The CDC states that improving hand hygiene is one of the most effective means of preventing the spread of infection within healthcare settings.

"We are very pleased that GMP will be working to develop and validate our proprietary new anti-infective technology for medical industry applications," said Jeff Hamner, vice-president of corporate R&D, P&G. "We believe the technology has excellent potential -- and GMP is well-positioned to lead the development for use in medical settings."

Under the terms of the agreement, GMP Companies also has the right to market medical formulations of the technology to commercial and industrial customers including government agencies, food service providers and schools. P&G will retain the rights to develop and market a retail version of the technology.

https://www.bionity.com/en/news/34958/gmp-companies-licenses-breakthrough-anti-infective-technology-from-procter-gamble.html